Treatment Information

Back

Melanoma treatment details. Chemotherapy, Biologic therapy.

Cambridge Biomedical Research Centre, Cambridge, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:Cambridge
Treatments:Chemotherapy, Biologic therapyHospital:Cambridge Biomedical Research Centre
Drugs:Journal:Link
Date:Jul 2011

Description:

Patients:
This phase II study involved 83 advanced melanoma patients who were not previously treated with chemotherapy. The median patient age was 56 years and 60% were male.

Treatment:
Patients were treated with the chemotherapy agent dacarbazine and the biologic therapy agent sorafenib, which is an angiogenesis inhibitor that inhibits blood supply to the tumor.

Toxicities:
There was one reported treatment-related death due to brain hemorrhage. Grade 3-4 neutropenia, low platelet count, and fatigue were also reported.

Results:
The median overall survival was 8.5 months.

Support:
Some of the authors were employed by Bayer Pharmaceuticals.

Correspondence: Dr. T Eisen; email: [email protected]



Back